163 related articles for article (PubMed ID: 37506762)
21. Recent trends in specialty pharma business model.
Ku MS
J Food Drug Anal; 2015 Dec; 23(4):595-608. PubMed ID: 28911475
[TBL] [Abstract][Full Text] [Related]
22. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca.
Janero DR
Expert Opin Drug Discov; 2012 Jun; 7(6):449-56. PubMed ID: 22540843
[TBL] [Abstract][Full Text] [Related]
23. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Forster SP; Stegmaier J; Spycher R; Seeger S
Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
[TBL] [Abstract][Full Text] [Related]
24. The productivity crisis in pharmaceutical R&D.
Pammolli F; Magazzini L; Riccaboni M
Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
[TBL] [Abstract][Full Text] [Related]
25. R&D implementation in a department of laboratory medicine and pathology: a systematic review based on pharmaceutical companies.
Feulefack J; Sergi C
Glob J Health Sci; 2015 Jan; 7(4):70-82. PubMed ID: 25946935
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.
Lexchin J
J Pharm Policy Pract; 2018; 11():5. PubMed ID: 29564139
[TBL] [Abstract][Full Text] [Related]
27. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
Schuhmacher A; Gatto A; Kuss M; Gassmann O; Hinder M
Drug Discov Today; 2021 Oct; 26(10):2226-2231. PubMed ID: 33965571
[TBL] [Abstract][Full Text] [Related]
28. Medicines as a Service: A New Commercial Model for Big Pharma in the Postblockbuster World.
Mattke S; Klautzer L; Mengistu T
Rand Health Q; 2012; 2(2):13. PubMed ID: 28083254
[TBL] [Abstract][Full Text] [Related]
29. Collaborative university-industry R&D practices supporting the pharmaceutical innovation process: Insights from a bibliometric review.
Ma Z; Augustijn K; de Esch IJP; Bossink B
Drug Discov Today; 2022 Aug; 27(8):2333-2341. PubMed ID: 35550437
[TBL] [Abstract][Full Text] [Related]
30. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
31. Do cost-sharing and entry deregulation curb pharmaceutical innovation?
Grossmann V
J Health Econ; 2013 Sep; 32(5):881-94. PubMed ID: 23896384
[TBL] [Abstract][Full Text] [Related]
32. 10 years after implementation of TRIPS obligations in India.
Pawar MD
Pharm Pat Anal; 2015; 4(3):147-59. PubMed ID: 26030078
[TBL] [Abstract][Full Text] [Related]
33. Can environmental regulations and R&D subsidies promote GTFP in pharmaceutical industry? Evidence from Chinese provincial panel data.
Yang YD
Front Public Health; 2022; 10():1018968. PubMed ID: 36225766
[TBL] [Abstract][Full Text] [Related]
34. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
Graul AI; Revel L; Tell M; Rosa E; Cruces E
Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
[TBL] [Abstract][Full Text] [Related]
35. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
36. Accessing external innovation in drug discovery and development.
Tufféry P
Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
[TBL] [Abstract][Full Text] [Related]
37. Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?
Kennedy KH; Gomez K; Thovmasian NJ; Chang DC
Drug Discov Today; 2023 Feb; 28(2):103456. PubMed ID: 36403884
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
39. Why and how have drug discovery strategies in pharma changed? What are the new mindsets?
Mignani S; Huber S; Tomás H; Rodrigues J; Majoral JP
Drug Discov Today; 2016 Feb; 21(2):239-49. PubMed ID: 26376356
[TBL] [Abstract][Full Text] [Related]
40. Key Factors to Improve Pharmaceutical Industry's R&D Productivity: A Case Study of Iranian Pharmaceutical Holding.
Shabani A; Rajabi S; Alipanahi N; Ahmadi Teymourlouy A
Med J Islam Repub Iran; 2022; 36():117. PubMed ID: 36447552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
